Margin of Insight
← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

Edwards Lifesciences Corporation

EW

FAVORABLE

May 27, 2026

Research Conclusion

BUY at $81.38. PWFV ~$103 (+27%). Composite FV ~$90-115 (+11-41%). Add below $72. Strong Add below $62. EW is the global leader in structural heart therapies — the dominant TAVR platform (65% US share) with an emerging second growth engine (TMTT: EVOQUE + PASCAL + SAPIEN M3). The stock is at 22.9x FY2027E adj. EPS — near the historical trough multiple — despite the best structural heart pipeline in the company's history. SAPIEN M3 (world's first FDA-approved TMVR, Dec 2025) is a free call option that the market hasn't valued. BUY.

Company Overview & Moat Assessment

Edwards Lifesciences (EW) is a pure-play structural heart company — the only large-cap medical device company entirely focused on transcatheter therapies for diseased heart valves. Its SAPIEN aortic valve has become the gold standard for TAVR, holding ~60-72% US market share after 15+ years of competition from Medtronic's Evolut franchise. The moat is built on physician training (50-200 cases to proficiency on SAPIEN delivery; switching to Evolut requires separate retraining), clinical data (the PARTNER trial series is 15 years of landmark RCT evidence — never expires), and brand (SAPIEN = TAVR in most cardiologists' mental model). After divesting Critical Care to BD in 2024 for ~$4.2B, EW is now a pure-play structural heart company with a pristine balance sheet ($2.9B net cash, minimal debt), three FDA-approved TMTT products (EVOQUE tricuspid replacement, PASCAL TEER, SAPIEN M3 TMVR), and a demographic tailwind from aging populations worldwide. FY2026 adj. EPS guidance of $2.95-3.05 (raised post-Q1 beat) represents +17% growth from the FY2025 base — the pure-play structural heart earnings engine accelerating.

▲ Bull Case

  • ◆TMTT Exceeds $1.2B FY2027 + SAPIEN M3 Early Commercial Ramp: EVOQUE/PASCAL beat street estimates as tricuspid and mitral repair reimbursement expands; SAPIEN M3 sees first meaningful hospital adoption in H2 2027; TMTT alone on track for $2B+ by FY2029; market begins valuing TMTT separately as a 'next TAVR' franchise; adj. EPS $4.25+ FY2027; P/E re-rates to 35x: $149 (+83%)
  • ◆Asymptomatic TAVR NCD Approval + Demographic Tailwind: CMS updates NCD for asymptomatic severe aortic stenosis; treatable population expands 20-30%; TAVR procedure volumes jump; Edwards' 65%+ share × larger TAM = step-change in revenue; TAVR revenues reach $6B+ by FY2029; adj. EPS $5+ by FY2030; long-term value creation exceeds current market cap
  • ◆SAPIEN M3 Becomes the TAVR of Mitral Disease: The TMVR market develops analogously to TAVR (from pilot to standard of care in 8-10 years); Edwards builds the same physician training moat in mitral that it built in aortic; first-mover advantage compounds; SAPIEN M3 reaches $1B+ by FY2031; stock re-rates to 40x+ earnings as a multi-decade compounder narrative emerges

▼ Bear Case

  • ◆Abbott Navitor Escalates + TMTT Reimbursement Delay: Abbott Navitor achieves broader US hospital adoption (competitive pricing, clinical data equivalence); EW's TAVR share falls to 55-58%; TMTT tricuspid reimbursement expansion takes 2 years longer than expected; EVOQUE volumes plateau; TMTT reaches only $850M by FY2027; adj. EPS $2.80; P/E 23x: $64 (-21%)
  • ◆SAPIEN M3 Commercialization Disappoints: Transseptal mitral valve replacement proves technically challenging to commercialize; learning curve is steeper than TAVR; reimbursement requires additional clinical data; SAPIEN M3 revenue is sub-$100M through FY2028; market downgrades TMTT optionality; multiple compresses toward 22x FY2027E EPS = $70-75
  • ◆Macro Healthcare Spending Pressure: Hospital capital spending freezes in a recession; structural heart procedures (elective in some cases, capital-intensive) decline; TAVR volume growth turns negative; TMTT hospital adoption delayed by budget constraints; multiple compression + earnings miss = double-hit; adj. EPS $2.50-2.70 FY2027; 20x = $50-55
Primary Debate on Wall Street

“Primary debate: 'Is EW a single-engine TAVR company with optionality, or a two-engine structural heart compounder in the early stages of TMTT scale-up?' The bear says: EW's growth for 20 years has been almost entirely TAVR. TMTT has been 'coming soon' for a long time — PASCAL commercially approved 2022, EVOQUE early 2024, and TMTT is still only $551M (9% of revenue). TAVR growth rate is slowing from 15%+ to 7-9% as the market matures. A company with its primary segment decelerating and its secondary segment still sub-scale is worth 22-25x, not 30-35x. The bull says: TMTT was $175M in FY2022 and is $551M in FY2025 (+57%/yr CAGR). FY2026 guidance is $740-780M — approaching $1B just 4 years after commercialization. SAPIEN M3 (Dec 2025 FDA) is the fourth product in the portfolio and has no competition. TAVR is not decelerating structurally — it's growing 7-9% on a $4.5B base, adding ~$350M/yr in incremental revenue. EW is a two-engine compounder at 22.9x FY2027E earnings. Resolution: TMTT quarterly revenue growth rate is the key data point. If EVOQUE + PASCAL + SAPIEN M3 combined reach $900M+ in FY2026 (above guidance midpoint $760M) and $1.1B+ in FY2027, the two-engine narrative is confirmed. If TMTT misses FY2026 guidance ($740-780M), the bear narrative strengthens.”

Top Catalysts
  • ◆Q2 2026 Earnings (~Aug 2026): TMTT revenue vs. $740-780M FY2026 guidance; TAVR growth rate; adj. EPS vs. $0.75-0.80 — CRITICAL
  • ◆SAPIEN M3 first hospital accounts trained + implanted (TMVR commercial initiation) — ongoing 2026
  • ◆Q3 2026: EVOQUE/PASCAL combined volumes; reimbursement coverage updates for tricuspid
  • ◆Late 2026/2027: CMS NCD process for asymptomatic severe aortic stenosis — any guidance on timeline
  • ◆Q4 2026: FY2026 adj. EPS vs. $3.00 midpoint; full-year TMTT vs. $760M guidance — thesis confirm
  • ◆Q1 2027: FY2027 guidance issued; TMTT trajectory toward $1B; SAPIEN M3 early volumes — thesis confirm
  • ◆2027-2028: TMTT approaching $1.0-1.5B as multiple products scale simultaneously — bull escalation
  • ◆Ongoing: Abbott Navitor US hospital adoption rate — primary competitive watch
Top Risks
  • ◆Abbott Navitor TAVR share escalation (MEDIUM probability / MEDIUM impact): Currently ~5-10% US share; risk of growing to 15-20% as physicians gain experience
  • ◆TMTT reimbursement slower than expected (MEDIUM / MEDIUM): Tricuspid coverage still expanding; delays in hospital adoption = TMTT misses guidance
  • ◆SAPIEN M3 commercialization challenges (MEDIUM / MEDIUM-HIGH): Novel procedure; learning curve; reimbursement uncertainty; could delay meaningful revenue to FY2028+
  • ◆FDA safety communication on any TMTT product (LOW / VERY HIGH): Any safety hold would severely impair the entire TMTT program — highest-severity risk
  • ◆Asymptomatic TAVR NCD not approved (MEDIUM / LOW-MEDIUM): Not in base case; risk is upside optionality doesn't materialize
  • ◆Hospital CapEx freeze in macro recession (MEDIUM / MEDIUM): Structural heart is somewhat elective; volume growth could slow in recession
  • ◆CEO transition execution risk (LOW / MEDIUM): Zovighian is 3 years into role; TMTT is his program; external replacement would elevate continuity risk

Full Memo Continues

5 more sections, locked

  • ●
    Valuation Range & DCF
    Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
  • ●
    Risk/Reward Assessment
    Position-sizing framework with explicit upside/downside skew and entry conditions.
  • ●
    Management & Capital Allocation
    Multi-year capital-allocation track record, incentive alignment, and management readout.
  • ●
    Monitoring Framework
    What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
  • ●
    Unresolved Questions
    Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/EW/memo
Authorization: Bearer spt_...

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.

Margin of Insight

For informational purposes only. Not investment advice.